MA

Muralidharan Ammanoor Sripriya

Active Director Designated Partner DIN 10710153
DIN 10710153 First appointment Jul 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Muralidharan Ammanoor Sripriya

Data last updated:

Muralidharan Ammanoor Sripriya is a Designated Partner at Glcfharmak Biotech Llp (since 2024).

DIN 10710153
Primary Designation Designated Partner
First Appointment 18 Jul 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner18 Jul 20242024Active

Board colleagues of Muralidharan Ammanoor Sripriya

NameDINCompanyDesignation
Muralidharan Ammanoor Rangamani10710151Glcfharmak Biotech LlpDesignated Partner
Pallave10710152Glcfharmak Biotech LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Glcfharmak Biotech Llp
Premium access

Shareholding and investment profile for Muralidharan Ammanoor Sripriya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Muralidharan Ammanoor Sripriya

Muralidharan Ammanoor Sripriya currently holds 1 directorship: Glcfharmak Biotech Llp (Designated Partner, since 18 Jul 2024).

Muralidharan Ammanoor Sripriya was first appointed on 18 Jul 2024 as Designated Partner at Glcfharmak Biotech Llp.

The current boards of Muralidharan Ammanoor Sripriya's companies include Muralidharan Ammanoor Rangamani (Glcfharmak Biotech Llp), Pallave (Glcfharmak Biotech Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available